MedWatch

Convatec upgrades 2021 sales forecast

In a Q3 trading update, UK-based Convatec has slightly increased its organic revenue growth expectation for the full year. Convatec now thinks revenue growth in the high end of the previously reported interval of 3.5-5 percent is likely.

Photo: Convatec

On Friday morning, UK-based medtech company Convatec, a competitor of Denmark-based Coloplast, released its third quarter report of the year.

In the Q3 report, Convatec has slightly upgraded its organic revenue growth expectation for the full year.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Britt Meelby Jensen wants to rebuild trust in Ambu

After a turbulent time for Ambu under Juan Jose Gonzalez’s reign, new chief executive appointee Britt Meelby Jensen aims to rebuild the trust in the medtech firm, which has downgraded its expectations seven times over the past three years.

Outgoing Ambu CEO commends colleagues

”A true privilege,” says Juan Jose Gonzalez, describing his time as CEO at Ambu, which came to an end with Thursday’s announcement that Britt Meelby Jensen would take over the role.

Further reading

Related articles

Latest news

See all jobs